Recruiting Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) NCT03938987 Conditions Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more Locations Foothills Medical Centre — Calgary, Alberta, Canada Tom Baker Cancer Centre — Calgary, Alberta, Canada Alberta Children's Hospital — Calgary, Alberta, Canada Cross Cancer Institute — Edmonton, Alberta, Canada View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081 Conditions B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +22 more Locations Peking University People'S Hospital — Beijing, Beijing Municipality, China View Trial Details
Active, Not Recruiting CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) NCT03774654 Conditions Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more Locations Houston Methodist Hospital — Houston, Texas, United States Texas Children's Hospital — Houston, Texas, United States View Trial Details
